drugset / Trial / NCT05351502
A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, dose-escalation and dose-expansion study comprised of a screening period, a single treatment session, an evaluation period of 21±3 days, and safety and survival follow-up period of up to 12 weeks post-treatment.
Timeline
- Start
- 2022-08-14
- Primary completion
- 2025-05-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitric Oxide | Other / unclassified | 25000 ppm | Other |
| Subject | Nitric Oxide | Other / unclassified | 50000 ppm | Other |
| Subject | Nitric Oxide | Other / unclassified | 100000 ppm | Other |